Yuhan
000100.KSPhase 3Founded in 1926, Yuhan Corporation is one of South Korea's most established and innovative pharmaceutical companies, operating with a dual focus on a profitable commercial business and a cutting-edge R&D pipeline. The company has achieved significant milestones, including the successful development and out-licensing of its EGFR inhibitor, lazertinib, to Janssen, and the commercialization of its leading diabetes franchise. Yuhan's strategy is built on internal R&D in oncology and immunology, strategic in-licensing, and global partnerships to expand its reach beyond the Korean market.
000100.KS · Stock Price
Historical price data
AI Company Overview
Founded in 1926, Yuhan Corporation is one of South Korea's most established and innovative pharmaceutical companies, operating with a dual focus on a profitable commercial business and a cutting-edge R&D pipeline. The company has achieved significant milestones, including the successful development and out-licensing of its EGFR inhibitor, lazertinib, to Janssen, and the commercialization of its leading diabetes franchise. Yuhan's strategy is built on internal R&D in oncology and immunology, strategic in-licensing, and global partnerships to expand its reach beyond the Korean market.
Technology Platform
Integrated drug discovery and development capabilities in small molecules and biologics, supported by a strategic open innovation model for in-licensing and out-licensing.
Pipeline Snapshot
118118 drugs in pipeline, 12 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Anplag(Sarpogrelate) + Placebo | Diabetic Nephropathy | Approved |
| YMC026 + Placebo | Respiratory Disease | Approved |
| statins, ezetimibe + Combination therapy | Coronary Artery Disease | Approved |
| Atorvastatin 20mg loading + Atorvastatin 80mg loading | Stable Angina | Approved |
| pregabalin sustained release tablet + pregabalin immediate release capsule | Neuropathic Pain | Approved |
Opportunities
Risk Factors
Competitive Landscape
Faces direct competition from global pharma giants like AstraZeneca (Tagrisso) in NSCLC and Merck in diabetes. Differentiation is achieved through targeted drug discovery (e.g., specific EGFR mutations), strategic partnerships for global scale, and a dominant, profitable home market in South Korea that funds innovation.
Company Info
Trading
Contact
Therapeutic Areas
Partners
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile